Getinge (OTCMKTS:GNGBY) Hits New 12-Month High – Should You Buy?

Getinge (OTCMKTS:GNGBY)’s share price hit a new 52-week high during trading on Tuesday. The company traded as high as $27.0525 and last traded at $26.8510, with a volume of 357 shares. The stock had previously closed at $26.82.

Analyst Ratings Changes

A number of brokerages recently weighed in on GNGBY. UBS Group began coverage on shares of Getinge in a report on Wednesday, September 2nd. They set a “hold” rating for the company. Pareto Securities cut Getinge from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 24th. Zacks Research lowered Getinge from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 17th. Finally, Nordea Equity Research cut shares of Getinge from a “buy” rating to a “hold” rating in a research report on Monday, August 31st. Four equities research analysts have rated the stock with a Hold rating. According to data from MarketBeat, Getinge has a consensus rating of “Hold”.

Getinge Price Performance

The company has a market capitalization of $7.31 billion, a P/E ratio of 24.41 and a beta of 0.95. The company has a fifty day moving average price of $25.24 and a 200 day moving average price of $22.55. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.31 and a quick ratio of 0.74.

Getinge (OTCMKTS:GNGBY) last issued its earnings results on Wednesday, October 21st. The company reported $0.32 earnings per share for the quarter. Getinge had a return on equity of 11.55% and a net margin of 8.20%. The company had revenue of $875.58 million for the quarter. On average, sell-side analysts forecast that Getinge will post 1.38 EPS for the current fiscal year.

Getinge Company Profile

Getinge AB is a Sweden-based medical technology company that develops products and solutions for hospitals, healthcare providers and life sciences organizations. Its offerings are designed to support patient care, surgical procedures, infection prevention and the development and production of pharmaceuticals and other medical products.

The company’s portfolio includes equipment for intensive care and cardiovascular procedures, operating-room systems, surgical instruments, sterilization and disinfection solutions, and products used in laboratories and biopharmaceutical manufacturing.